company background image
YMAB

Y-mAbs Therapeutics NasdaqGS:YMAB Stock Report

Last Price

US$14.35

Market Cap

US$627.4m

7D

2.7%

1Y

-49.7%

Updated

29 Sep, 2022

Data

Company Financials +
YMAB fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

YMAB Stock Overview

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States.

Y-mAbs Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Y-mAbs Therapeutics
Historical stock prices
Current Share PriceUS$14.35
52 Week HighUS$29.53
52 Week LowUS$6.50
Beta1.12
1 Month Change-7.72%
3 Month Change-6.45%
1 Year Change-49.72%
3 Year Change-42.62%
5 Year Changen/a
Change since IPO-40.21%

Recent News & Updates

Aug 13
Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

The latest analyst coverage could presage a bad day for Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ), with the analysts...

Shareholder Returns

YMABUS BiotechsUS Market
7D2.7%1.0%-3.1%
1Y-49.7%-25.8%-21.5%

Return vs Industry: YMAB underperformed the US Biotechs industry which returned -24.2% over the past year.

Return vs Market: YMAB underperformed the US Market which returned -20.3% over the past year.

Price Volatility

Is YMAB's price volatile compared to industry and market?
YMAB volatility
YMAB Average Weekly Movement11.0%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: YMAB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: YMAB's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2015148Thomas Gadhttps://www.ymabs.com

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Y-mAbs Therapeutics Fundamentals Summary

How do Y-mAbs Therapeutics's earnings and revenue compare to its market cap?
YMAB fundamental statistics
Market CapUS$627.38m
Earnings (TTM)-US$134.95m
Revenue (TTM)US$39.85m

15.7x

P/S Ratio

-4.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
YMAB income statement (TTM)
RevenueUS$39.85m
Cost of RevenueUS$5.08m
Gross ProfitUS$34.76m
Other ExpensesUS$169.71m
Earnings-US$134.95m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.09
Gross Margin87.24%
Net Profit Margin-338.68%
Debt/Equity Ratio0%

How did YMAB perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is YMAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for YMAB?

Other financial metrics that can be useful for relative valuation.

YMAB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue12.5x
Enterprise Value/EBITDA-3.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does YMAB's PS Ratio compare to its peers?

YMAB PS Ratio vs Peers
The above table shows the PS ratio for YMAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average12.6x
ALEC Alector
2.6x-0.5%US$780.2m
QURE uniQure
13.5x40.8%US$837.4m
IDYA IDEAYA Biosciences
22.4x37.0%US$653.6m
AUPH Aurinia Pharmaceuticals
12x38.5%US$1.1b
YMAB Y-mAbs Therapeutics
15.7x45.9%US$627.4m

Price-To-Sales vs Peers: YMAB is expensive based on its Price-To-Sales Ratio (15.7x) compared to the peer average (12.6x).


Price to Earnings Ratio vs Industry

How does YMAB's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: YMAB is expensive based on its Price-To-Sales Ratio (15.7x) compared to the US Biotechs industry average (13.8x)


Price to Sales Ratio vs Fair Ratio

What is YMAB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

YMAB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio15.7x
Fair PS Ratio22.8x

Price-To-Sales vs Fair Ratio: YMAB is good value based on its Price-To-Sales Ratio (15.7x) compared to the estimated Fair Price-To-Sales Ratio (22.8x).


Share Price vs Fair Value

What is the Fair Price of YMAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate YMAB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate YMAB's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Y-mAbs Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


50.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: YMAB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: YMAB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: YMAB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: YMAB's revenue (45.9% per year) is forecast to grow faster than the US market (7.7% per year).

High Growth Revenue: YMAB's revenue (45.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: YMAB is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Y-mAbs Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-23.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: YMAB is currently unprofitable.

Growing Profit Margin: YMAB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: YMAB is unprofitable, and losses have increased over the past 5 years at a rate of 23.3% per year.

Accelerating Growth: Unable to compare YMAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: YMAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: YMAB has a negative Return on Equity (-102.7%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Y-mAbs Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: YMAB's short term assets ($153.9M) exceed its short term liabilities ($29.5M).

Long Term Liabilities: YMAB's short term assets ($153.9M) exceed its long term liabilities ($4.3M).


Debt to Equity History and Analysis

Debt Level: YMAB is debt free.

Reducing Debt: YMAB has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: YMAB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: YMAB has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 29.7% each year.


Discover healthy companies

Dividend

What is Y-mAbs Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Y-mAbs Therapeutics Dividend Yield vs Market
How does Y-mAbs Therapeutics dividend yield compare to the market?
SegmentDividend Yield
Company (Y-mAbs Therapeutics)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (Y-mAbs Therapeutics)0%

Notable Dividend: Unable to evaluate YMAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate YMAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if YMAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if YMAB's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as YMAB has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Thomas Gad (52 yo)

7.42yrs

Tenure

US$1,867,701

Compensation

Mr. Thomas Gad founded Y-mAbs Therapeutics, Inc. in April 2015 and serves as its Interim Chief Executive Officer since April 22, 2022, serves as its President, Head of Business Development & Strategy and D...


CEO Compensation Analysis

Thomas Gad's Compensation vs Y-mAbs Therapeutics Earnings
How has Thomas Gad's remuneration changed compared to Y-mAbs Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$135m

Mar 31 2022n/an/a

-US$117m

Dec 31 2021US$2mUS$500k

-US$55m

Sep 30 2021n/an/a

-US$38m

Jun 30 2021n/an/a

-US$42m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$4mUS$471k

-US$119m

Sep 30 2020n/an/a

-US$123m

Jun 30 2020n/an/a

-US$114m

Mar 31 2020n/an/a

-US$91m

Dec 31 2019US$3mUS$440k

-US$81m

Sep 30 2019n/an/a

-US$72m

Jun 30 2019n/an/a

-US$59m

Mar 31 2019n/an/a

-US$52m

Dec 31 2018US$3mUS$395k

-US$43m

Sep 30 2018n/an/a

-US$38m

Jun 30 2018n/an/a

-US$31m

Mar 31 2018n/an/a

-US$24m

Dec 31 2017US$598kUS$350k

-US$19m

Compensation vs Market: Thomas's total compensation ($USD1.87M) is below average for companies of similar size in the US market ($USD4.03M).

Compensation vs Earnings: Thomas's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: YMAB's management team is considered experienced (4.8 years average tenure).


Board Members

Experienced Board: YMAB's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqGS:YMAB Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
09 Feb 22SellUS$2,021,188Thomas GadIndividual281,170US$7.59
04 Feb 22SellUS$1,055,558Thomas GadIndividual136,164US$7.90
24 Jan 22SellUS$936,412Thomas GadIndividual88,055US$10.96
21 Jan 22SellUS$2,033,105Thomas GadIndividual183,085US$11.35
19 Jan 22SellUS$760,676Thomas GadIndividual69,814US$11.46
07 Dec 21SellUS$901,074Thomas GadIndividual54,000US$17.58
30 Nov 21SellUS$746,571Thomas GadIndividual43,607US$17.16

Ownership Breakdown

What is the ownership structure of YMAB?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,866,5244.3%
Private Companies4,178,4659.6%
VC/PE Firms5,285,23212.1%
General Public8,448,69219.3%
Institutions23,940,63654.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 72.45% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.56%
Wg Biotech Aps
4,178,465$60.0m0%no data
7.07%
HBM Partners Ltd.
3,090,954$44.4m0%4.64%
6.81%
BlackRock, Inc.
2,976,221$42.7m1.06%no data
6.75%
Polar Capital Holdings plc
2,952,671$42.4m2.61%0.23%
6.44%
AllianceBernstein L.P.
2,815,865$40.4m-5.16%0.02%
5.02%
Sofinnova Investment, Inc.
2,194,278$31.5m0%2.24%
4.51%
FMR LLC
1,970,844$28.3m0.03%no data
4.41%
The Vanguard Group, Inc.
1,929,916$27.7m7.55%no data
4.28%
Wellington Management Group LLP
1,870,379$26.8m-2.1%0.01%
3.99%
State Street Global Advisors, Inc.
1,743,142$25.0m-24.5%no data
1.94%
Medical Strategy GmbH, Asset Management Arm
849,367$12.2m2.26%0.85%
1.54%
Thomas Gad
675,032$9.7m0%no data
1.43%
Geode Capital Management, LLC
626,168$9.0m7.31%no data
1.42%
Claus Juan Moller San Pedro
622,928$8.9m0%no data
1.01%
Mpm Oncology Impact Management, L.P.
443,702$6.4m0%1.87%
0.95%
Walleye Capital LLC
416,140$6.0m0%0.09%
0.91%
Artal Group S.A.
400,000$5.7m0%0.3%
0.81%
Morgan Stanley, Investment Banking and Brokerage Investments
353,673$5.1m-25.26%no data
0.76%
Northern Trust Global Investments
333,098$4.8m1.79%no data
0.57%
Charles Schwab Investment Management, Inc.
247,608$3.6m5.93%no data
0.5%
Dimensional Fund Advisors LP
219,967$3.2m19.96%no data
0.48%
Perceptive Advisors LLC
212,018$3.0m0%0.1%
0.44%
Memorial Sloan Kettering Cancer Center, Endowment Arm
191,176$2.7m0%9.9%
0.41%
Bo Kruse
181,077$2.6m0%no data
0.41%
Lombard Odier Asset Management (Switzerland) SA
180,933$2.6m-18.42%0.06%

Company Information

Y-mAbs Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Y-mAbs Therapeutics, Inc.
  • Ticker: YMAB
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$627.376m
  • Shares outstanding: 43.72m
  • Website: https://www.ymabs.com

Number of Employees


Location

  • Y-mAbs Therapeutics, Inc.
  • 230 Park Avenue
  • Suite 3350
  • New York
  • New York
  • 10169
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
YMABNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDSep 2018

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/29 00:00
End of Day Share Price2022/09/29 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.